



Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness

Aaron M. Frutos, PhD, MPH

On behalf of CDC Influenza Vaccine Effectiveness Collaborators

Advisory Committee on Immunization Practices

February 28, 2024

CDC Influenza Vaccine Effectiveness Networks

Four networks to evaluate vaccine effectiveness (VE) against laboratory-confirmed influenza for children, adolescents, and adults in the outpatient and inpatient settings

CDC Influenza Vaccine Effectiveness Networks


Investigating Respiratory Viruses in the Acutely Ill (IVY)

New Vaccine Surveillance Network (NVSN)


U.S. Flu Vaccine Effectiveness Network (US Flu VE)

Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION)


These networks include all ages across settings




NVSN: all settings




US Flu VE: Outpatient clinic and ED/UC




VISION: ED/UC & hospitalization




IVY: hospitalization




US Flu VE: Outpatient clinic and ED/UC




VISION: ED/UC & hospitalization



These networks include all ages across settings



CDC influenza VE networks include patients from 22 states



2023-2024 Influenza VE Methods

Enrollees: Have acute respiratory illness

Dates of enrollment: Fall 2023- Early 2024

Design: Test-negative design

- Comparing vaccination odds among case patients with influenza confirmed by molecular assay versus control patients testing negative for influenza and SARS-CoV-2
- Vaccination status: receipt of any 2023–24 seasonal flu vaccine according to medical records, immunization registries, claims data, and/or self-report

2023-2024 Influenza VE Methods

Analysis: $VE = (1 - \text{adjusted OR}) \times 100\%$

- Adjusted for geographic region, age, calendar time of illness
 - IVY, US Flu VE, and VISION also adjusted for sex and race and ethnicity
 - US Flu VE also adjusted for days between illness onset and enrollment and self-reported general health status.
- VE estimates were calculated for influenza A subtypes A(H1N1)pdm09 and A(H3N2) when possible
 - Subtype not available for VISION
- VE was not estimated for some age groups and settings when sample size was small or when models did not converge


Pediatric VE

(aged 6 months–17 years)


Pediatric VE against any influenza

Influenza test result by influenza vaccination status, no. vaccinated/Total (%)			
	Influenza-positive	Influenza-negative	VE (95% CI)
NVSN (Outpatient)	123/622 (20)	793/2,577 (31)	59 (48, 67)
US Flu VE (Outpatient)	29/283 (10)	182/736 (25)	67 (48, 80)
VISION (Outpatient)	961/6,068 (16)	4,579/15,274 (30)	60 (57, 64)
NVSN (Inpatient)	29/128 (23)	543/1,321 (41)	61 (40, 75)
VISION (Inpatient)	21/113 (19)	299/921 (32)	52 (16, 72)


Pediatric VE against any influenza




Pediatric VE against influenza A




Pediatric VE against influenza A(H1N1)pdm09



Pediatric VE against influenza A(H3N2)



Pediatric VE against influenza B




Adult VE

(aged ≥ 18 years)


Adult VE against any influenza

	Influenza test result by influenza vaccination status, no. vaccinated/Total (%)		
	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	177/568 (31)	803/1,807 (44)	33 (16, 47)
VISION (Outpatient)	4,501/18,385 (24)	21,356/52,657 (41)	49 (47, 51)
IVY (Inpatient)	200/632 (32)	1,517/3,872 (39)	44 (32, 54)
VISION (Inpatient)	728/1,839 (40)	7,425/14,168 (52)	41 (34, 47)


Adult VE against any influenza




Adult VE against influenza A




Adult VE against influenza A(H1N1)pdm09



Adult VE against influenza A(H3N2)



Adult VE against influenza B




Adult (aged ≥ 65) VE


Adult (aged ≥ 65) VE against any influenza

Influenza test result by influenza vaccination status, no. vaccinated/Total (%)			
	Influenza-positive	Influenza-negative	VE (95% CI)
US Flu VE (Outpatient)	41/79 (52)	300/439 (68)	51 (14, 72)
VISION (Outpatient)	1,944/3,687 (53)	12,162/19,571 (62)	41 (36, 45)
IVY (Inpatient)	113/249 (45)	938/1,945 (48)	42 (23, 56)
VISION (Inpatient)	531/1,066 (50)	6,058/10,118 (60)	42 (34, 50)


Adult (aged ≥ 65) VE against any influenza



Adult (aged ≥ 65) VE against influenza A



Adult (aged ≥ 65) VE against influenza B



Discussion



Summary of four CDC influenza VE networks

Vaccination with a 2023-24 influenza vaccine **reduced the risk for** medically attended influenza **outpatient visits** and **hospitalizations** among **children, adolescents, and adults across 22 US States**

Vaccination was effective against **both influenza A (mostly subtype A(H1N1)pdm09) and B (lineage Victoria) viruses** that have circulated this season

Results were **consistent across networks**

Thank you

We'd like to thank our many collaborators from CDC, IVY, NVSN, US Flu VE, and VISION

Aaron M. Frutos, PhD, MPH

Influenza Division

National Center for Immunization and Respiratory Diseases


AFrutos@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Overall VE (pediatric and adults) by season*



*Estimates are from US Flu VE except for 2022-23 which are from a study from WI